GI Symposium: Spotlight on Peritoneal Serface Malignancy and HIPEC
This day-long educational activity is designed to highlight challenges, controversies and advances in the field of metastatic colorectal cancer. The content will focus on the clinical care of patients with advanced GI cancer and topics will include current chemotherapy regimens in addition to the utility of radiation and surgery. Often the evolving field of cancer care and its complexity of coordination is not understood fully. This symposium will serve as a resource to clearly define the current guidelines, anticipated challenges and the expected results. The intended audience is primarily Medical Oncologists, General Surgeons and Surgical Oncologists, Radiation Oncologists, Interventional Radiologists/Oncologists, Radiologists, Oncology Affiliated Practice Providers, Oncology Nurses and Palliative Care Providers. Invited speakers include well-known academic surgeons who are well-published in their respective fields and who can provide up-to-date summaries of the topics. There will be a specific focus on new and innovative Regional Cancer Therapies.
Regional Cancer Therapies are new and innovative in the field of cancer care. While the number of patients with advanced cancer diagnoses has increased there remains a lack of knowledge regarding regional cancer therapies, which has led to a decreased level of referrals from providers. This symposium will highlight the advances in the management of metastatic colorectal cancer.
Please note a non-refundable $3.00 processing fee will be assessed on all registrations.
Target Audience
•Medical Oncologists
•General Surgeons
•Surgical Oncologists
•Radiation Oncologists
•Interventional Radiologists/Oncologists
•Radiologists
•Oncology Affiliated Practice Providers
•Oncology Nurses
•Palliative Care Providers
Learning Objectives
•Discuss liver, peritoneal, nodal and pulmonary metastases as well as the advantages of molecular diagnoses.
•Discuss evolving techniques and treatment strategies for the management of carcinomatosis.
•Discuss and define program for regional therapies, patients’ care decision tree and outcomes
KEYNOTE SPEAKER
Andrea Hayes-Jordan, MD
Associate Professor
Department of Pediatric Surgery
The University of Texas Medical School at Houston
Associate Professor
Department of Surgical Oncology and Pediatrics
The University of Texas M. D. Anderson Cancer Center
FEATURED MCW SPEAKERS
Callisia Clarke, MD
Assistant Professor
Division of Surgical Oncology
Ben George, MD
Associate Professor of Medicine
Division of Hematology and Oncology
Harveshp Mogal, MD
Assistant Professor
Division of Surgical Oncology
Associate Program Director for Regional Therapies
Stacy O’Connor, MD, MPH, MMSc
Assistant Professor of Radiology
Medical Director, Imaging IT Operations
Section of Abdominal/Body Imaging
Division of Diagnostic Radiology
Section of Informatics
Division of Imaging Services
Wendy Peltier, MD
Associate Professor of Medicine
Division of Hematology and Oncology
Jared Robbins, MD
Assistant Professor
Department of Radiation Oncology
James Thomas, MD, PhD
Associate Director, Translational Research
Medical Director, Clinical Trials Office
Section Head, Solid Tumor Oncology
Professor
Division of Hematology and Oncology
In accordance with the ACCMEⓇ standard for Commercial Support Number 6, all in control of content have NO relevant financial relationships to disclose with the exception of the following person(s):
| Name | Company | Role |
Ben George, MD | Celgene, Cook Medical, Foundation Medicine, Meremack, Ipsen | Consultant |
In accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Available Credit
- 5.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 5.00 Hours of ParticipationHours of Participation credit.

Facebook
X
LinkedIn
Forward